Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets
NCT04275492Phase 1Terminated
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pramipexole in Parkinson's disease (PD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 2 more. Started Jul 2020; status: terminated.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04275492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275492.